• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report.

作者信息

He Xiaoyuan, Zhang Xiaomei, Yu Zhengyu, Meng Juanxia, Jiang Yanyu, Zhao Yifan, Lyu Hairong, Bai Xue, Xiao Xia, Zhao Mingfeng

机构信息

Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China.

Nankai University School of Medicine, Tianjin, People's Republic of China.

出版信息

Blood Adv. 2025 Mar 11;9(5):1159-1162. doi: 10.1182/bloodadvances.2024014982.

DOI:10.1182/bloodadvances.2024014982
PMID:39729519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11925504/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0b7/11925504/66e9c8a53093/BLOODA_ADV-2024-014982-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0b7/11925504/66e9c8a53093/BLOODA_ADV-2024-014982-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0b7/11925504/66e9c8a53093/BLOODA_ADV-2024-014982-gr1.jpg

相似文献

1
Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report.抗FcRL5嵌合抗原受体T细胞在抗BCMA和抗GPRC5D嵌合抗原受体T细胞进展后对演进性多发性骨髓瘤表现出抗骨髓瘤活性：一例报告
Blood Adv. 2025 Mar 11;9(5):1159-1162. doi: 10.1182/bloodadvances.2024014982.
2
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.抗 BCMA/GPRC5D 双特异性 CAR T 细胞治疗复发或难治性多发性骨髓瘤患者的单臂、单中心、1 期临床试验
Lancet Haematol. 2024 Oct;11(10):e751-e760. doi: 10.1016/S2352-3026(24)00176-5. Epub 2024 Jul 23.
3
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.抗GPRC5D嵌合抗原受体T细胞疗法作为抗BCMA嵌合抗原受体T细胞疗法后进展性多发性骨髓瘤患者的挽救治疗：一项单中心、单臂、2期试验
Lancet Haematol. 2025 May;12(5):e365-e375. doi: 10.1016/S2352-3026(25)00048-1. Epub 2025 Apr 12.
4
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.抗 BCMA CAR-T 细胞疗法在伴有髓外疾病的复发/难治性多发性骨髓瘤患者中的应用：两项临床试验的单中心分析。
Front Immunol. 2021 Oct 29;12:755866. doi: 10.3389/fimmu.2021.755866. eCollection 2021.
5
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.BCMA 或 GPRC5D 靶向免疫疗法治疗多发性骨髓瘤中抗原逃逸的机制。
Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31.
6
Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma.靶向BCMA和GPRC5D的嵌合抗原受体T细胞在复发或难治性多发性骨髓瘤中的疗效和安全性
Front Immunol. 2024 Dec 23;15:1466443. doi: 10.3389/fimmu.2024.1466443. eCollection 2024.
7
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.GPRC5D 是一种经理性设计的 CAR T 细胞免疫疗法的多发性骨髓瘤的靶点。
Sci Transl Med. 2019 Mar 27;11(485). doi: 10.1126/scitranslmed.aau7746.
8
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.抗 G 蛋白偶联受体，C 类组 5 成员 D 嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤患者：单臂、Ⅱ期试验。
J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7.
9
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.复发或难治性多发性骨髓瘤患者中的GPRC5D嵌合抗原受体T细胞（OriCAR-017）（北极星研究）：一项首次人体、单中心、单臂1期试验。
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.
10
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.除了 BCMA，为什么 GPRC5D 是正确的选择：抗 BCMA 药物治疗后复发时的免疫治疗策略。
Cancer Immunol Immunother. 2023 Dec;72(12):3931-3937. doi: 10.1007/s00262-023-03559-4. Epub 2023 Nov 4.

引用本文的文献

1
Targets for CAR Therapy in Multiple Myeloma.多发性骨髓瘤中CAR疗法的靶点
Int J Mol Sci. 2025 Jun 24;26(13):6051. doi: 10.3390/ijms26136051.

本文引用的文献

1
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.PD-1 下调通过维持细胞记忆表型和减少衰竭来增强 CAR-T 细胞的抗肿瘤效率。
J Immunother Cancer. 2024 Apr 8;12(4):e008429. doi: 10.1136/jitc-2023-008429.
2
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.Fc 受体样蛋白 5（FCRL5）导向嵌合抗原受体 T 细胞对多发性骨髓瘤具有抗肿瘤活性。
Signal Transduct Target Ther. 2024 Jan 12;9(1):16. doi: 10.1038/s41392-023-01702-2.
3
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.
表达具有仅含人重链抗原结合域的抗BCMA嵌合抗原受体的T细胞具有快速抗骨髓瘤活性。
Mol Ther. 2024 Feb 7;32(2):503-526. doi: 10.1016/j.ymthe.2023.12.018. Epub 2023 Dec 28.
4
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.伊达基奥仑赛治疗复发/难治性多发性骨髓瘤：1 期试验的 18 个月随访的事后分析。
Nat Med. 2023 Sep;29(9):2286-2294. doi: 10.1038/s41591-023-02496-0. Epub 2023 Aug 17.
5
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.针对复发或难治性多发性骨髓瘤的 GPRC5D 免疫疗法：2022 年 ASH 年会的最新进展。
J Hematol Oncol. 2023 Jun 5;16(1):60. doi: 10.1186/s13045-023-01461-1.
6
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.抗 G 蛋白偶联受体，C 类组 5 成员 D 嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤患者：单臂、Ⅱ期试验。
J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7.
7
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.复发或难治性多发性骨髓瘤患者中的GPRC5D嵌合抗原受体T细胞（OriCAR-017）（北极星研究）：一项首次人体、单中心、单臂1期试验。
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.
8
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).Ciltacabtagene Autoleucel，一种抗 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法，在复发/难治性多发性骨髓瘤（CARTIFAN-1）中国患者中的 II 期、开放标签研究。
J Clin Oncol. 2023 Feb 20;41(6):1275-1284. doi: 10.1200/JCO.22.00690. Epub 2022 Oct 21.
9
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.新型国产抗 BCMA CAR T 细胞的研发与生产用于治疗复发/难治性多发性骨髓瘤：I 期临床试验结果。
Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628.
10
GPRC5D-Targeted CAR T Cells for Myeloma.GPRC5D 靶向 CAR T 细胞治疗骨髓瘤。
N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900.